This is an old revision of the document!
Ciaran Lawlor
Ciaran Lawlor is an American biotechnology entrepreneur based in Boston, Massachusetts.
History
COVID-19
Lawlor co-authored a paper titled “The Near-Term Outlook for COVID-19 Therapeutic Treatments” published by the Boston Consulting Group on May 8, 2020. The paper presented a favourable outlook for the use of the experimental drug remdesivir over a variety of other options to treat COVID-19. Lawlor's co-authors were Jordon Walker, Ahad Wahid and Josh Kellar.1)
A follow-up article was published on May 14, 2020, titled “The Timelines and Implications for COVID-19 Vaccines”. It was co-authored with Kellar, Wahid, Emily Serazin, Andrew Rodriguez and Philip Berk.2)
External links
1)
Lawlor, C., Wahid, A., Walker, J., & Kellar, J. (2020). The Near-Term Outlook for COVID-19 Therapeutic Treatments. Boston Consulting Group. https://web.archive.org/web/20230422204237/https://web-assets.bcg.com/img-src/BCG-The-Near-Term-Outlook-for-COVID-19-Therapeutic-Treatments-May-2020_tcm9-246799.pdf
2)
Lawlor, C., Kellar, J., Serazin, E., Rodriguez, A., Berk, P., & Wahid, A. (2020, May 14). The Timelines and Implications for COVID-19 Vaccines. Boston Consulting Group. http://archive.today/2023.06.14-235609/https://www.bcg.com/en-ca/publications/2020/covid-vaccines-timelines-implications